SQI Diagnostics Ships Automated Multi-Biomarker SQiDworks(TM) Platform to the Cleveland Clinic for Validation Trials



    TORONTO, Feb. 19 /CNW/ - SQI Diagnostics Inc. (TSX-Venture: SQD), a
medical systems automation company focused on evolving laboratory-based
biomarker testing, today announced that it has shipped its automated
SQiDworks(TM) platform to the Cleveland Clinic in Cleveland, Ohio. The
Cleveland Clinic laboratory is the second external validation partner to
receive the platform and will evaluate its analytic performance along with SQI
Diagnostics' QuantiSpot(TM) RA assay, generating data to be used by SQI
Diagnostics for regulatory submissions.
    "Having our platform undergo validation trials by one of the leading
hospitals in the US is a significant achievement for SQI Diagnostics and
demonstrates the desire these hospitals have for a breakthrough technology
that could save them time and money when conducting high volume multiple
biomarker tests," said Claude Ricks, CEO of SQI Diagnostics. "We anticipate
completing this validation trial in the first half of 2008 and intend to
submit these results to support our regulatory filings shortly thereafter."
    The data from the validation trials being conducted at Mount Sinai
Hospital (Toronto) and the Cleveland Clinic (Cleveland Ohio), together with
internal validation trial data, will be used to seek regulatory clearance for
the automated SQiDworks platform and the Company's lead QuantiSpot microarray
panel for rheumatoid arthritis (QuantiSpot RA). SQI Diagnostics continues to
develop its menu of QuantiSpot assays for autoimmune diseases and plans to
initiate validation trials for its second multiplex assay for antiphospholipid
syndrome, (APS) biomarkers in 2008.

    About SQiDworks(TM)

    SQiDworks(TM) is a fully-automated fluidics workstation, scanner and
analytical device used to process SQI Diagnostics' proprietary QuantiSpot
microarray test devices. The platform fully integrates all assay steps for
hands-free work-flow and is designed to be compatible with standard lab
automation systems. When combined with the Company's QuantiSpot multiplexed
tests SQiDworks can produce quantified determinations for over 900 individual
test results per hour resulting in significant laboratory efficiencies and
cost-savings.

    About QuantiSpot(TM)

    The SQI Diagnostics microarray device, QuantiSpot(TM), is a multiplexed
assay consumable for use with the SQiDworks automated workstation. QuantiSpot
tests are currently being developed for the detection and quantification of
biomarkers used in the diagnosis of Autoimmune Disease and Infectious Disease.
When combined with the SQiDworks fully-automated workstation users are able to
process multiplexed assays to quantify serum concentrations of up to 12
individual biomarkers or the qualitative detection of up to 24 biomarkers per
patient.

    About SQI Diagnostics

    SQI Diagnostics is a medical systems automation company focused on
evolving laboratory-based biomarker testing. Using automation and proprietary
miniaturization technologies, SQI Diagnostics significantly improves the
economies of scale for laboratories performing multiple biomarker testing at
high volumes, allowing them to deliver patient results faster using less labor
and fewer resources. SQI Diagnostics' platform has a user-friendly interface,
100% quality control, high sample throughput and offers a more efficient
alternative to current testing options. SQI Diagnostics' initial products
target the $1.4 billion autoimmune disease market, with initial products for
Rheumatoid Arthritis and Thrombosis scheduled for launch in 2007. SQI
Diagnostics is based in Toronto, Canada. For further information please visit
www.sqidiagnostics.com.

    Certain information in this press release is based on beliefs and
assumptions of the Company's senior management and information currently
available to it that may constitute forward-looking information within the
meaning of securities laws. Such statements reflect the current views of the
Company with respect to future events and are subject to certain risks and
uncertainties. Actual results, events, and performance may differ materially.
Readers are cautioned not to place undue reliance on these forward-looking
statements.

    This release was prepared by management of the Company who takes full
    responsibility for its contents. The TSX Venture Exchange has not
    reviewed and does not accept responsibility for the adequacy or accuracy
    of this news release.

    %SEDAR: 00021000E




For further information:

For further information: Chief Financial Officer, Andrew Morris, (416)
674-9500 ext. 229, amorris@sqidiagnostics.com; Investor Relations, James
Smith, (416) 815-0700 ext. 229, jsmith@equicomgroup.com


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890